Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2-Reference-Cited by-同舟云学术

Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2

Published:2021-12-23 Issue:7898 Volume:602 Page:676-681
ISSN:0028-0836
Container-title:Nature
language:en
Short-container-title:Nature

Author:

Liu Lihong,Iketani Sho,Guo Yicheng^ORCID,Chan Jasper F.-W.^ORCID,Wang Maple,Liu Liyuan,Luo Yang^ORCID,Chu Hin^ORCID,Huang Yiming,Nair Manoj S.^ORCID,Yu Jian,Chik Kenn K.-H.,Yuen Terrence T.-T.,Yoon Chaemin,To Kelvin K.-W.^ORCID,Chen Honglin^ORCID,Yin Michael T.,Sobieszczyk Magdalena E.,Huang Yaoxing^ORCID,Wang Harris H.^ORCID,Sheng Zizhang,Yuen Kwok-Yung^ORCID,Ho David D.^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Multidisciplinary

Link

https://www.nature.com/articles/s41586-021-04388-0.pdf

Reference48 articles.

1. Shu, Y. & McCauley, J. GISAID: global initiative on sharing all influenza data—from vision to reality. Euro Surveill. 22, 30494 (2017).

2. Grabowski, F., Kochańczyk, M. & Lipniacki, T. Omicron strain spreads with the doubling time of 3.2—3.6 days in South Africa province of Gauteng that achieved herd immunity to Delta variant. Preprint at https://doi.org/10.1101/2021.12.08.21267494 (2021).

3. Scott, L. et al. Track Omicron’s spread with molecular data. Science 374, 1454–1455 (2021).

4. Wang, P. et al. Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7. Nature 593, 130–135 (2021).

5. Abu-Raddad, L. J., Chemaitelly, H. & Butt, A. A. Effectiveness of the BNT162b2 COVID-19 vaccine against the B.1.1.7 and B.1.351 variants. N. Engl. J. Med. 385, 187–189 (2021).

Cited by 1091 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Dynamic expedition of leading mutations in SARS-CoV-2 spike glycoproteins;Computational and Structural Biotechnology Journal;2024-12

2. The role of convalescent plasma and hyperimmune immunoglobulins in the COVID-19 pandemic, including implications for future preparedness;Frontiers in Immunology;2024-09-09

3. Evaluating the risk of SARS-CoV-2 reinfection with the Omicron or Delta variant in Wales, UK;PLOS ONE;2024-09-06

4. Assessment of age-dependent effects during the transmission of Omicron and the outcomes of booster campaign vaccination strategies;Applied Mathematical Modelling;2024-09

5. Structural review of SARS-CoV-2 antiviral targets;Structure;2024-09